Ascending thoracic aortic aneurysms and dissections (ATAAD) are interrelated cardiovascular diseases that carry high mortality.] Current approaches to pharmacologic prevention of ATAAD are ineffective, particularly in patients with sporadic disease. Although there is a critical need to develop new treatment strategies, a major barrier to this goal is a poor understanding of the molecular mechanisms that trigger and then promote aortic degeneration in sporadic ATAAD. Therefore, our long-term goal is to improve the under- standing of the pathobiology of aortic wall degeneration in hope of developing new pharmacological strategies to prevent ATAAD formation and progression. The overall objective of this application is to systematically define the role of the NLRP3 inflammasome cascade, a multiprotein platform involved in amplifying intracellular stress responses, in promoting aortic destruction and the extent to which this cascade represents a therapeutic target against ATAAD. The central hypotheses are: (1) the NLRP3-ASC-caspase-1 cascade promotes aortic degeneration by promoting smooth muscle cell contractile dysfunction and aortic destruction, and (2) treatment with pharmacological inhibitors of this cascade will prevent ATAAD. These central hypotheses will be tested through three specific aims, each of which focuses on specific hypotheses based on our preliminary data. [In the first aim, we will seek to prove our hypothesis that the NLRP3- ASC-caspase-1 inflammasome cascade promotes ascending aortic wall inflammatory cell infiltration, matrix destruction, contractile dysfunction, and biomechanical failure through a series of experiments with a mouse model of sporadic ATAAD. In the second aim, we will seek to prove the hypothesis that the inflammasome cascade directly cleaves and degrades myosin heavy chain and tropomyosin, and thus promotes SMC contractile dysfunction. We will also determine whether intracellular stress activates the inflammasome cascade and confirm the association of intracellular stress and the inflammasome in human ATAAD tissue. In the third aim, we will test the hypothesis that NLRP3 inhibitors (glyburide, parthenolide and MCC950) will prevent ascending aortic destruction and disease progression in our mouse model of sporadic ATAAD.] The proposed research is significant because it will determine how the inflammasome cascade is activated, how this cascade promotes ATAAD development, and the extent to which an inflammasome inhibitor can prevent ATAAD. This research is innovative because it represents a new and substantive departure from the status quo, namely the current pharmacologic approaches to preventing aortic disease progression. The development of a new, effective pharmacological prevention strategy would have an important positive effect on disease prognosis by delaying or obviating invasive procedures in patients presenting with early-stage ascending aortic disease, suppressing disease progression in patients who are poor candidates for surgical treatment, and improving the durability of surgical aortic repairs.
The proposed research is relevant to public health because ascending thoracic aortic aneurysms and dissections are frequent causes of death in the United States, largely because current approaches to pharmacologic prevention are ineffective. The project is relevant to the NHLBI's mission because it focuses on treatment and prevention of life-threating cardiovascular diseases; the development of a new, effective therapeutic agent would help prevent aortic disease progression and save lives in patients with these conditions.
|Wu, Darrell; Ren, Pingping; Zheng, Yanqiu et al. (2017) NLRP3 (Nucleotide Oligomerization Domain-Like Receptor Family, Pyrin Domain Containing 3)-Caspase-1 Inflammasome Degrades Contractile Proteins: Implications for Aortic Biomechanical Dysfunction and Aneurysm and Dissection Formation. Arterioscler Thromb Vasc Biol 37:694-706|